[Federal Register: July 17, 2007 (Volume 72, Number 136)]
[Notices]
[Page 39114-39118]
[DOCID:fr17jy07-85]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56041; File No. SR-NYSEArca-2007-43]

Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing
and Order Granting Accelerated Approval of Proposed Rule Change To List
and Trade Shares of the iShares COMEX Gold Trust

July 11, 2007.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on May 11, 2007, NYSE Arca, Inc. (the ``Exchange''), through its
wholly-owned subsidiary, NYSE Arca Equities, Inc. (``NYSE Arca
Equities''), filed with the Securities and Exchange Commission
(``Commission'') the proposed rule change as described in Items I and
II below, which Items have been substantially prepared by the Exchange.
This order provides notice of the proposed rule change and approves the
proposed rule change on an accelerated basis.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to list and trade shares (``Shares'') of the
iShares [supreg] \3\ COMEX [supreg] \4\ Gold Trust (``Trust'') pursuant
to NYSE Arca Equities Rule 8.201. The text of the proposed rule change
is available at the Exchange, the Commission's Public Reference Room,
and http://www.nyse.com.

---------------------------------------------------------------------------

    \3\ ``iShares'' is a registered trademark of Barclays Global
Investors, N.A.
    \4\ ``COMEX'' is a registered service mark of Commodity
Exchange, Inc., a subsidiary of the New York Mercantile Exchange,
Inc. (``NYMEX''). COMEX is operated by Commodity Exchange, Inc. and
the Tokyo Commodity Exchange. Open outcry trading of gold futures on
COMEX is conducted from 8:20 a.m. Eastern Time (``ET'') until 1:30
p.m. ET, and electronic trading of such gold futures is conducted
from 6 p.m. ET until 5:15 p.m. ET via the CME Globex [reg] trading
platform, Sunday through Friday. Thus, except for brief breaks (45
minutes) to switch between open outcry and electronic trading in the
evening and the morning, gold futures trade almost 24 hours per day,
five business days per week.
---------------------------------------------------------------------------

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item III below. The Exchange has prepared summaries, set forth in
Sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    Pursuant to NYSE Arca Equities Rule 8.201, which permits the
trading of Commodity-Based Trust Shares \5\ either by listing or
pursuant to unlisted trading privileges (``UTP''), the Exchange
proposes to list and trade the Shares. The Shares are currently listed
on the American Stock Exchange LLC (``Amex''),\6\ and the Exchange
currently trades the Shares pursuant to UTP.\7\ The Exchange represents
that the Shares satisfy the requirements of NYSE Arca Equities Rule
8.201 and thereby qualify for listing on the Exchange.
---------------------------------------------------------------------------

    \5\ As defined in NYSE Arca Equities Rule 8.201(c)(1),
``Commodity-Based Trust Shares'' are securities that: (1) Are issued
by a trust that holds a specified commodity deposited with the
trust; (2) are issued by such trust in a specified aggregate minimum
number in return for a deposit of a quantity of the underlying
commodity; and (3) when aggregated in the same specified minimum
number, may be redeemed at a holder's request by such trust which
would deliver to the redeeming holder the quantity of the underlying
commodity.
    \6\ See Securities Exchange Act Release No. 51058 (January 19,
2005), 70 FR 3749 (January 26, 2005) (SR-Amex-2004-38) (granting
approval to list and trade the Shares on Amex). See also Securities
Exchange Act Release No. 50792 (December 3, 2004), 69 FR 71446
(December 9, 2004) (SR-Amex-2004-38) (providing notice of Amex's
proposal to list and trade the Shares) (``Amex Notice'').
    \7\ See Securities Exchange Act Release No. 51067 (January 21,
2005), 70 FR 3952 (January 27, 2005) (SR-PCX-2004-132) (approving
NYSE Arca Equities Rule 8.201 and the trading of the Shares pursuant
to UTP) (``UTP Order'').
---------------------------------------------------------------------------

    The Shares represent beneficial ownership interests in the net
assets of the Trust, which holds gold bullion. The objective of the
Trust is for the value of the Shares to reflect, at any given time, the
price of gold owned by the Trust at that time, less the Trust's
expenses and liabilities. The Trust is not actively managed and does
not engage in any activities designed to obtain a profit from, or to
ameliorate losses caused by, changes in the price of gold. The Trust is
neither an investment company registered under the Investment Company
Act of 1940 nor a commodity pool for purposes of the Commodity Exchange
Act.\8\ Barclays Global Investors International Inc., a Delaware
corporation and a subsidiary of Barclays Bank PLC, is the sponsor of
the Trust (``Sponsor''). The Shares are not obligations of, and are not
guaranteed by, the Sponsor or any of its respective subsidiaries or
affiliates.
---------------------------------------------------------------------------

    \8\ The Exchange states that the Trust does not trade in gold
futures contracts. The Trust takes delivery of physical gold that
complies with certain gold delivery rules. Because the Trust does
not trade in gold futures contracts on any futures exchange, the
Trust is not regulated as a commodity pool, and is not operated by a
commodity pool operator.
---------------------------------------------------------------------------

    A detailed discussion of the gold market, including the over-the-
counter gold market and the gold futures exchanges, gold market
regulation, COMEX gold futures contracts, the process for creations and
redemptions of the Shares, certificates evidencing the Shares, and
Trust distributions, among others, can be found in the Amex Notice and
in the Trust Prospectus.\9\
---------------------------------------------------------------------------

    \9\ See supra note 6; see also iShares COMEX Gold Trust
Prospectus dated March 1, 2007 (Registration Statement No. 333-
140874) (``Prospectus''). E-mail from Timothy J. Malinowski,
Director, NYSE Group, Inc., to Edward Cho, Special Counsel, Division
of Market Regulation, Commission, dated July 11, 2007 (confirming
that additional information on the gold markets, the Trust, and the
Shares can be found in the Amex Notice and the Prospectus, as
supplemented).
---------------------------------------------------------------------------

    The Web site for the Trust at http://www.ishares.com, which is

publicly accessible at no charge, contains the following information
about the Shares: (a) The prior business day's net asset value
(``NAV'') per Share; \10\ (b) Basket Gold Amount; \11\ (c) the reported
Share closing price; (d) the present day's Indicative Basket Gold
Amount; \12\ (e) the mid-point of the bid-ask price in relation to the
NAV as of the time the

NAV is calculated (``Bid-Ask Price''); \13\ (f) calculation of the
premium or discount of such price against such NAV; (g) data in chart
form displaying the frequency distribution of discounts and premiums of
the Bid-Ask Price against the NAV, within appropriate ranges for each
of the four previous calendar quarters; (h) the Prospectus; and (i)
other applicable quantitative information, such as expense ratios,
trading volumes, and the total return of the Shares. The Exchange also
provides a hyperlink on its Web site to the Trust's Web site.
---------------------------------------------------------------------------

    \10\ The Exchange states that it would obtain a representation
from the Trust, prior to listing, that the NAV per Share would be
calculated daily and made available to all market participants at
the same time.
    \11\ The ``Basket Gold Amount'' is the corresponding amount of
gold, measured in fine ounces, to be exchanged for an issuance of a
basket of 50,000 Shares (each such basket, a ``Basket''), for the
purpose of creating and redeeming the Shares.
    \12\ The ``Indicative Basket Gold Amount'' is the indicative
amount of gold to be deposited for issuance of the Shares that
Authorized Participants can use. Because the creation/redemption
process is based entirely on the physical delivery of gold (and does
not contemplate a cash component), the actual number of fine ounces
required for the Indicative Basket Gold Amount would not change
intra-day, even though the value of the Indicative Basket Gold
Amount may change based on the market price of gold.
    \13\ The Bid-Ask Price of Shares is determined using the highest
bid and lowest offer as of the time of calculation of the NAV.
---------------------------------------------------------------------------

    The Exchange would make available, through the facilities of the
Consolidated Tape Association (``CTA''), quotation information
including the last sale price for the Shares, the daily trading volume,
closing prices, and the NAV for the Shares from the previous day. In
addition, the Exchange or a major market data vendor would disseminate
each day through the facilities of the CTA the number of Shares
outstanding and the Indicative Trust Value (``ITV'') on a per-Share
basis at least every 15 seconds \14\ from 9:30 a.m. to 4:15 p.m.
ET.\15\ The ITV is calculated based on the estimated amount of gold
required for creations and redemptions on any particular day (e.g., the
Indicative Basket Gold Amount) and a price of gold derived from the
most recently reported trade price in the active gold futures contract.
The prices reported for the active contract month are adjusted based on
the prior day's spread differential between settlement values for that
contract and the spot month contract. In the event that the spot month
contract is also the active contract, the last sale price for the
active contract is not adjusted.\16\
---------------------------------------------------------------------------

    \14\ E-mail from Timothy J. Malinowski, Director, NYSE Group,
Inc., to Edward Cho, Special Counsel, Division of Market Regulation,
Commission, dated July 9, 2007 (confirming the updated ITV would be
disseminated at least every 15 seconds).
    \15\ The Exchange states that the ITV will not reflect changes
to the price of gold between the close of trading at COMEX, which is
typically 1:30 p.m. ET, and the open of trading on the NYMEX ACCESS
market at 2 p.m. ET. While the market for the gold futures is open
for trading, the ITV can be expected to closely approximate the
value per Share of the Indicative Basket Gold Amount. The ITV on a
per-Share basis disseminated during the hours from 9:30 a.m. to 4:15
p.m. ET should not be viewed as a real-time update of the NAV, which
is calculated only once a day. E-mail from Timothy J. Malinowski,
Director, NYSE Group, Inc., to Edward Cho, Special Counsel, Division
of Market Regulation, Commission, dated July 9, 2007. See also UTP
Order, 70 FR at 3956.
    \16\ E-mail from Timothy J. Malinowski, Director, NYSE Group,
Inc., to Edward Cho, Special Counsel, Division of Market Regulation,
Commission, dated July 9, 2007 (confirming the ITV calculation
methodology). See also UTP Order, 70 FR at 3956 n.33.
---------------------------------------------------------------------------

    Shortly after 4 p.m. ET each business day, the Trustee,\17\ the
Exchange, and the Sponsor would disseminate the NAV for the Shares, the
Basket Gold Amount (for orders placed during the day), and the
Indicative Basket Gold Amount (for use by Authorized Participants \18\
contemplating placing orders the following business day). The Basket
Gold Amount, the Indicative Basket Gold Amount, and the NAV are
communicated by the Trustee to all Authorized Participants via
facsimile or e-mail and are available on the Trust's Web site.
---------------------------------------------------------------------------

    \17\ The Bank of New York serves as the Trustee and is
responsible for the day-to-day administration of the Trust,
including processing orders for the creation and redemption of
Shares, coordinating the receipt and delivery of gold transferred
to, or by, the Trust in connection with each creation and redemption
of Shares, calculating the NAV and the adjusted NAV of the Trust on
each business day, and selling the Trust's gold as needed to cover
the Trust's expenses.
    \18\ An ``Authorized Participant'' is a person who, at the time
of submitting to the Trustee an order to create or redeem one of
more Baskets, (1) is a registered broker-dealer, (2) is a Depository
Trust Company participant or an indirect participant, and (3) has in
effect a valid authorized participant agreement.
---------------------------------------------------------------------------

    The Exchange states that information on gold prices and gold
markets is available on public Internet Web sites and through
professional and subscription services. In most instances, real-time
information is available only for a fee, and information available
free-of-charge is subject to delay (typically 20 minutes). The Exchange
also states that investors may obtain on a 24-hour basis gold pricing
information based on the spot price for a troy ounce of gold from
various financial information service providers, such as Reuters and
Bloomberg. Reuters and Bloomberg provide at no charge on their Web
sites delayed information regarding the spot price of gold and last
sale prices of gold futures, as well as information about news and
developments in the gold market. Reuters and Bloomberg also offer a
professional service to subscribers for a fee that provides information
on gold prices directly from market participants. In addition, an
organization named EBS provides an electronic trading platform to
institutions such as bullion banks and dealers for the trading of spot
gold, as well as a feed of live streaming prices to Reuters and
Moneyline Telerate subscribers.
    The Exchange further represents that complete real-time data for
gold futures and options prices traded on COMEX is available by
subscription from Reuters and Bloomberg. The closing price and
settlement prices of the COMEX gold futures contracts are publicly
available from NYMEX at http://www.nymex.com, automated quotation

systems, published or other public sources, or on-line information
services such as Bloomberg or Reuters. NYMEX also provides delayed
futures and options information on current and past trading sessions
and market news free of charge on its Web site.
    The Exchange states that the Shares are subject to the criteria for
initial and continued listing of Commodity-Based Trust Shares under
NYSE Arca Equities Rule 8.201. As indicated above, the Shares are
currently trading on the Exchange pursuant to UTP. A minimum of 100,000
Shares would be required to be outstanding when the Shares are listed.
This minimum number of Shares required to be outstanding is comparable
to requirements that have been applied to previously listed series of
exchange-traded funds. The Exchange believes that the proposed minimum
number of Shares outstanding at the start of trading is sufficient to
provide market liquidity. In addition, the Exchange represents that the
Trust is required to comply with Rule 10A-3 under the Act \19\ for the
initial and continued listing of the Shares.
---------------------------------------------------------------------------

    \19\ 17 CFR 240.10A-3.
---------------------------------------------------------------------------

    The Exchange deems the Shares to be equity securities, thus
rendering trading in the Shares subject to the Exchange's existing
rules governing the trading of equity securities. The trading hours for
the Shares on the Exchange are the same as those set forth in NYSE Arca
Equities Rule 7.34 (Opening, Core, and Late Trading Sessions, 4 a.m. ET
to 8 p.m. ET).\20\
---------------------------------------------------------------------------

    \20\ The Exchange states that, while the Shares would trade on
the Exchange until 8 p.m. ET, liquidity in the over-the-counter
market for gold generally decreases after 1:30 p.m. ET when daily
trading at COMEX and other world gold trading centers ends. Trading
spreads and the resulting premium or discount on the Shares may
widen as a result of reduced liquidity in the over-the-counter gold
market. The Exchange does not believe that the Shares would trade at
a material discount or premium to the value of the underlying gold
held by the Trust because of arbitrage opportunities.
---------------------------------------------------------------------------

    With respect to trading halts, the Exchange may consider all
relevant factors in exercising its discretion to halt or suspend
trading in the Shares. Trading may be halted because of market
conditions or for reasons that, in the view of the Exchange, make
trading in the Shares inadvisable. These reasons may include (1) the
extent to which trading is not occurring in the underlying COMEX gold
futures contract, or (2) whether other unusual conditions or
circumstances detrimental

to the maintenance of a fair and orderly market are present. In
addition, trading in the Shares could be halted pursuant to the
Exchange's ``circuit breaker'' rule \21\ or by the halt or suspension
of trading of the underlying gold. The Exchange further notes that, if
the ITV or the value of the underlying gold is not being calculated or
widely disseminated as required, the Exchange may halt trading during
the day in which the interruption to the calculation or wide
dissemination of the ITV or the value of the underlying gold occurs. If
the interruption to the calculation or wide dissemination of the ITV or
the value of the underlying gold persists past the trading day in which
it occurred, the Exchange would halt trading no later than the
beginning of the trading day following the interruption.
---------------------------------------------------------------------------

    \21\ See NYSE Arca Equities Rule 7.12 (Trading Halts Due to
Extraordinary Market Volatility).
---------------------------------------------------------------------------

    The Exchange intends to utilize its existing surveillance
procedures applicable to derivative products to monitor trading in the
Shares. The Exchange represents that these procedures are adequate to
properly monitor Exchange trading of the Shares in all trading sessions
and to deter and detect violations of Exchange rules. The Exchange may
also obtain information via the Intermarket Surveillance Group
(``ISG'') from other exchanges that are members or affiliate members of
ISG. In addition, the Exchange has an information sharing agreement in
place with NYMEX for the purpose of providing information in connection
with trading in or related to gold futures contracts traded on COMEX.
Furthermore, the Exchange states that the Shares are subject to NYSE
Arca Equities Rule 8.201(g)-(i), which set forth certain restrictions
on ETP Holders \22\ acting as registered market makers in the Shares to
facilitate surveillance. The Exchange also has a general policy
prohibiting the distribution of material, non-public information by its
employees.
---------------------------------------------------------------------------

    \22\ An ETP Holder is a registered broker or dealer that has
been issued an Equity Trading Permit (ETP) by NYSE Arca Equities.
---------------------------------------------------------------------------

    Prior to the commencement of trading, the Exchange will inform its
ETP Holders in an Information Bulletin (``Bulletin'') of the special
characteristics and risks associated with trading the Shares.
Specifically, the Bulletin will discuss the following: (a) Description
of the Shares; (b) the risks involved in trading the Shares during the
Opening and Late Trading Sessions when an updated ITV will not be
calculated or publicly disseminated; \23\ (c) the procedures for
purchases and redemptions of Shares in Baskets (and that Shares are not
individually redeemable); (d) NYSE Arca Equities Rule 9.2(a), which
imposes a duty of due diligence on its ETP Holders to learn the
essential facts relating to every customer prior to trading the Shares;
(e) how information regarding the ITV is disseminated; (f) the
requirement that ETP Holders deliver a prospectus to investors
purchasing newly issued Shares prior to or concurrently with the
confirmation of a transaction; and (g) other relevant trading
information. In addition, the Bulletin will reference that the Trust is
subject to various fees and expenses, the number of ounces of gold
required to create a Basket or to be delivered upon redemption of a
Basket would gradually decrease over time because the Shares comprising
a Basket would represent a decreasing amount of gold due to the sale of
the Trust's gold to pay Trust expenses, and that there is no regulated
source of last-sale information regarding physical gold. The Bulletin
will also disclose that the NAV for the Shares will be calculated after
4 p.m. ET each trading day, based on the COMEX daily settlement value,
which is disseminated shortly after 1:30 p.m. ET each trading day and
discuss any exemptive, no-action, and/or interpretive relief granted by
the Commission from any rules under the Act.\24\
---------------------------------------------------------------------------

    \23\ E-mail from Timothy J. Malinowski, Director, NYSE Group,
Inc., to Edward Cho, Special Counsel, Division of Market Regulation,
Commission, dated July 9, 2007 (confirming that such risks will be
disclosed in the Bulletin).
    \24\ The Exchange represents that the Commission has granted
exemptions from, or interpretive or no-action advice regarding,
Section 11(d)(1) of the Act (15 U.S.C. 78k(d)(1)), Rules 10a-1 (17
CFR 240.10a-1) and 11d1-2 (17 CFR 240.11d1-2), Rule 200(g) of
Regulation SHO (17 CFR 242.200(g)), and Rules 101 and 102 of
Regulation M (17 CFR 242.101 and 17 CFR 242.102) under the Act, in
respect of trading of the Shares. See Letter from James A.
Brigagliano, Assistant Director, Office of Trading Practices,
Division of Market Regulation, Commission, to David Yeres, Esq.,
Clifford Chance U.S. LLP, dated January 27, 2005. See also Letter
from Brian A. Bussey, Assistant Chief Counsel, Division of Market
Regulation, Commission, to David Yeres, Esq., Clifford Chance U.S.
LLP, dated December 12, 2005.
---------------------------------------------------------------------------

2. Statutory Basis
    The proposal is consistent with Section 6(b) of the Act,\25\ in
general, and Section 6(b)(5) of the Act,\26\ in particular, in that it
is designed to prevent fraudulent and manipulative acts and practices,
to promote just and equitable principles of trade, to foster
cooperation and coordination with persons engaged in facilitating
transactions in securities, and to remove impediments to and perfect
the mechanism of a free and open market and a national market system.
---------------------------------------------------------------------------

    \25\ 15 U.S.C. 78f(b).
    \26\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
result in any burden on competition that is not necessary or
appropriate in furtherance of the purpose of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants or Others

    The Exchange has neither solicited nor received written comments on
the proposed rule change.

III. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-NYSEArca-2007-43 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-NYSEArca-2007-43. This
file number should be included on the subject line if e-mail is used.
To help the Commission process and review your comments more
efficiently, please use only one method. The Commission will post all
comments on the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments,

all written statements with respect to the proposed rule change that
are filed with the Commission, and all written communications relating
to the proposed rule change between the Commission and any person,
other than those that may be withheld from the public in accordance
with the provisions of 5 U.S.C. 552, will be available for inspection
and copying in the Commission's Public Reference Room, 100 F Street,
NE., Washington,

DC 20549, on official business days between the hours of 10 a.m. and 3
p.m. Copies of such filing also will be available for inspection and
copying at the principal offices of the Exchange. All comments received
will be posted without change; the Commission does not edit personal
identifying information from submissions. You should submit only
information that you wish to make available publicly. All submissions
should refer to File Number SR-NYSEArca-2007-43 and should be submitted
on or before August 7, 2007.

IV. Commission's Findings and Order Granting Accelerated Approval of
the Proposed Rule Change

    After careful review, the Commission finds that the proposed rule
change is consistent with the requirements of the Act and the rules and
regulations thereunder applicable to a national securities
exchange.\27\ In particular, the Commission finds that the proposed
rule change is consistent with Section 6(b)(5) of the Act,\28\ which
requires that an exchange have rules designed, among other things, to
promote just and equitable principles of trade, to remove impediments
to and perfect the mechanism of a free and open market and a national
market system, and, in general, to protect investors and the public
interest. The Commission notes that it previously approved the original
listing and trading of the Shares on Amex, and the instant proposal is
substantively identical to the previous Amex proposal.\29\
---------------------------------------------------------------------------

    \27\ In approving this rule change, the Commission notes that it
has considered the proposed rule's impact on efficiency,
competition, and capital formation. See 15 U.S.C. 78c(f).
    \28\ 15 U.S.C. 78f(b)(5).
    \29\ See supra note 6.
---------------------------------------------------------------------------

    The Commission further believes that the proposal is consistent
with Section 11A(a)(1)(C)(iii) of the Act,\30\ which sets forth
Congress' finding that it is in the public interest and appropriate for
the protection of investors and the maintenance of fair and orderly
markets to assure the availability to brokers, dealers, and investors
of information with respect to quotations for and transactions in
securities. The Exchange would make available, through the facilities
of the CTA, quotation and last sale price information for the Shares,
the daily trading volume, closing prices, and the NAV for the Shares
from the previous day. In addition, the Exchange or a major market data
vendor would disseminate each day through the facilities of the CTA the
number of Shares outstanding and the ITV on a per-Share basis at least
every 15 seconds from 9:30 a.m. to 4:15 p.m. ET. The Web site for the
Trust contains information related to the NAV, including the Bid-Ask
Price, the Basket Gold Amount, the Indicative Basket Gold Amount,
calculation information and data related to the premium or discount of
the Bid-Ask Price against the NAV, the Prospectus, and other applicable
quantitative information, including trading volume data, total return
of the Shares, expense ratios, and reported Share closing prices.
Shortly after 4 p.m. ET each business day, the Trustee, the Exchange,
and the Sponsor would disseminate the NAV for the Shares, the Basket
Gold Amount, and the Indicative Basket Gold Amount. Information on gold
prices and gold markets is available on public Web sites and through
professional subscription services, and investors may obtain on a 24-
hour basis gold pricing information based on the spot price for a troy
ounce of gold from various financial information service providers.
Closing and settlement prices of gold futures contracts traded on COMEX
are publicly available from NYMEX's Web site, automated quotation
systems, published or other public sources, or on-line information
services such as Bloomberg or Reuters. NYMEX also provides delayed
futures and options information on current and past trading sessions
and market news free of charge.
---------------------------------------------------------------------------

    \30\ 15 U.S.C. 78k-1(a)(1)(C)(iii).
---------------------------------------------------------------------------

    Furthermore, the Commission believes that the proposal to list and
trade the Shares is reasonably designed to promote fair disclosure of
information that may be necessary to price the Shares appropriately.
The Commission notes that the Exchange will obtain a representation
from the Trust, prior to listing, that the NAV per Share would be
calculated daily and made available to all market participants at the
same time.\31\ In addition, NYSE Arca Equities Rule 8.201(i) provides
that, in connection with trading in an underlying physical commodity,
related commodity futures or options on commodity futures, or any other
related commodity derivative, including Commodity-Based Trust Shares,
an ETP Holder acting as a Market Maker (as defined in NYSE Arca
Equities Rule 1.1(u)) in the Shares is restricted from using any
material non-public information received from any person associated
with such ETP Holder who is trading such underlying physical commodity,
related commodity futures or options on commodity futures, or other
related commodity derivatives.
---------------------------------------------------------------------------

    \31\ See supra note 10.
---------------------------------------------------------------------------

    The Commission also believes that the Exchange's trading halt rules
are reasonably designed to prevent trading in the Shares when
transparency is impaired. NYSE Arca Equities Rule 8.201(e)(2) provides
that, when the Exchange is the listing market, if the value of the
underlying commodity or ITV is no longer calculated or available on at
least a 15-second delayed basis, the Exchange would consider suspending
trading in the Shares. The Exchange further represents that if the
interruption to the calculation or wide dissemination of the value of
the underlying gold or ITV persists past the trading day in which it
occurred, the Exchange would halt trading no later than the beginning
of the trading day following the interruption. NYSE Arca Equities Rule
8.201(e)(2) also provides that the Exchange may seek to delist the
Shares in the event the value of the underlying gold or ITV is no
longer calculated or available as required.
    The Commission further believes that the trading rules and
procedures to which the Shares will be subject pursuant to this
proposal are consistent with the Act. The Exchange has represented that
any securities listed pursuant to this proposal will be deemed equity
securities, and subject to existing Exchange rules governing the
trading of equity securities.
    In support of this proposal, the Exchange has made the following
representations:
    (1) The Exchange's surveillance procedures are adequate to address
any concerns associated with the trading of the Shares.
    (2) The Exchange would inform its members in an Information
Bulletin of the special characteristics and risks associated with
trading the Shares, including risks inherent with trading the Shares
during the Opening and Late Trading Sessions when the updated ITV is
not calculated and disseminated and suitability recommendation
requirements.
    (3) The Exchange would require its members to deliver a prospectus
or product description to investors purchasing Shares prior to or
concurrently with a transaction in such Shares and will note this
prospectus delivery requirement in the Information Bulletin.

This approval order is conditioned on the Exchange's adherence to these
representations.
    The Commission finds good cause for approving this proposal before
the thirtieth day after the publication of notice thereof in the
Federal Register. As noted above, the Commission

previously approved the original listing and trading of the Shares on
Amex and the trading of the Shares pursuant to UTP on the Exchange.\32\
The Commission presently is not aware of any regulatory issue that
should cause it to revisit those findings or would preclude the listing
and trading of the Shares on the Exchange. Accelerating approval of
this proposed rule change would allow the Shares to be listed on the
Exchange without undue delay and continuously traded without
interruption, to the benefit of investors.
---------------------------------------------------------------------------

    \32\ See supra notes 6 and 7.
---------------------------------------------------------------------------

V. Conclusion

    It is therefore ordered, pursuant to Section 19(b)(2) of the
Act,\33\ that the proposed rule change (SR-NYSEArca-2007-43) be, and it
hereby is, approved on an accelerated basis.
---------------------------------------------------------------------------

    \33\ 15 U.S.C. 78s(b)(2).

    For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\34\
---------------------------------------------------------------------------

    \34\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
[FR Doc. E7-13749 Filed 7-16-07; 8:45 am]

BILLING CODE 8010-01-P


Hanna, L., J. M. Peters, L. M. Wiley, et al. 1996. Comparative effects of essential and nonessential metals on preimplantation mouse embryo development [ abstract]. Faseb. J. 10( 3): A783.

Hanzlik, R. P., R. Stitt and G. J. Traiger. 1980. Toxic effects of methylcyclopentadienyl manganese tricarbonyl ( MMT) in rats: Role of metabolism. Toxicol. Appl. Pharmacol. 56: 353 360 ( as cited in U. S. EPA, 1994).

Hart, D. A. 1978. Evidence that manganese inhibits an early event during stimulation of lymphocytes by mitogens. Exp. Cell. Res. 113: 139 150 ( as cited in ATSDR, 2000).

Hatano S., K. Aihara, Y. Nishi and T. Usui. 1985. Trace elements ( copper, zinc, manganese, and selenium) in plasma and erythrocytes in relation to dietary intake during infancy. J. Pedia. Gastroent. Nutr. 4: 87 92.

He, P., D. Liu, G. Zhang, et al. 1994. [ Effects of high level manganese sewage irrigation on children's neurobehavior.] Chung Hua Yu Fang I Hsueh Tsa Chih] 28: 216 218. ( Chinese).

Hauser, R. A., T. A. Zesiewicz, A. S. Rosemurgy, C. Martinez, and C. W. Olanow. 1994. Manganese intoxication and chronic liver failure. Ann. Neurol. 36: 871 5.

Health and Welfare Canada ( HWC). 1978. Methylcyclopentadienyl manganese tricarbonyl ( MMT): As an assessment of the human health implications of its use as a gasoline additive. Environmental Health Directorate. Health Protection Branch, Ottawa, Canada. 78 EHD 21.

Hellou, J., L. Fancy and J. Payne. 1992. Concentrations of twenty four elements in bluefin tuna, Thunnus thynnus, from the Northwest Atlantic. Chemosphere 24( 2): 211 218.

Hietanen, E., J. Kilpio and H. Savolainen. 1981. Neurochemical and biotransformational enzyme responses to manganese exposure in rats. Arch. Environ. Contam. Toxicol. 10( 3): 339 345.

Hinderer, R. K. 1979. Toxicity studies of methylcyclopentadienyl manganese tricarbonyl ( MMT). Am. Ind. Hyg. Assoc. J. 40: 164 167 ( as cited in U. S. EPA, 1994).

Holbrook, D. J., Jr., M. E. Washington, H. B. Leake, et al. 1975. Studies on the evaluation of the toxicity of various salts of lead, manganese, platinum, and palladium. Environ. Health Perspect. 10: 95 101. 10 11 Manganese   February 2003 Holzgraefe, M., W. Poser, H. Kijewski, et al. 1986. Chronic enteral poisoning caused by potassium permanganate: A case report. J. Toxicol. Clin. Toxicol. 24: 235 244 ( as cited in ATSDR, 2000).

Horiuchi, K., S. Horiguchi, N. Tanaka, et al. 1967. Manganese contesnts in the whole blood, urine and feces of a healthy Japanese population. Osaka City Med. J. 13( 2): 151 163 ( original in Japanese).

Huang, C. C., N. S. Chu, C. S. Lu, R. S. Chen, and D. B. Calne. 1998. Long term progression in chronic manganism: ten years of follow up. Neurology 50: 698 700.

Hurley, L. S., D. E. Wolley and P. S. Timiras. 1961. Threshold and pattern of electro shock seizures in ataxic manganese deficient rats. Proc. Soc. Exp. Biol. Med. 106: 343 346 ( as cited in ATSDR, 2000).

Hurley, L. S., C. L. Keen and D. L. Baly. 1984. Manganese deficiency and toxicity: effects on carbohydrate metabolism in the rat. Neurotoxicology 5( 1): 97 104 ( as cited in ATSDR, 2000).

Hysell, D. K., W. Moore, Sr., J. F. Stara, et al. 1974. Oral toxicity of methylcyclopentadienyl manganese tricarbonyl ( MMT) in rats. Environ. Res. 7: 158 168 ( as cited in U. S. EPA, 1994).

Imam, Z. and S. V. Chandra. 1975. Histochemical alterations in rabbit testis produced by manganese chloride. Toxicol. Appl. Pharmacol. 32( 3): 534 544.

Institute of Medicine ( IOM). 2002. Dietary Reference Intakes: Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington DC: National Academy Press. Pp. 10 1  10 22.

Iwami, O., T. Watanabe, T., C. S., Moon, et al. 1994. Motor neuron disease on the Kii Peninsula of Japan: excess manganese intake from food coupled with low magnesium in drinking water as a risk factor. Sci. Total Environ. 149: 121 135 ( as cited in ATSDR, 2000).

Järvinen, R. and A. Ahlström. 1975. Effect of the dietary manganese level on tissue manganese, iron, copper, and zinc concentrations in female rats and their fetuses. Med. Biol. 53: 93 99.

Joardar, M. and A. Sharma. 1990. Comparison of clastogenicity of inorganic Mn administered in cationic and anionic forms in vivo. Mutat. Res. 240( 3): 159 163.

Johnson, P. E., G. I. Lykken and E. D. Korynta. 1991. Absorption and biological half life in humans of intrinsic 54Mn tracers from foods of plant origin. J. Nutr. 121: 711 717.

Jonderko, G. 1965. Calcium, manganese, inorganic phosphorus, sodium, potassium and iron level in the blood serum in the acute experimental manganism. Med. Pr. 16( 4): 288 292 ( original in Polish). 10 12 Manganese   February 2003 Kafritsa, Y., J. Fell, S. Long, et al. 1998. Long term outcome of brain manganese deposition in patients on home parenteral nutrition. Arch. Dis. Child 79: 263 265.

Kanematsu, N., M. Hara and T. Kada. 1980. Rec assay and mutagenicity studies on metal compounds. Mutat. Res. 77: 109 116 ( as cited in ATSDR, 2000).

Kaplan, R. W. 1962. Problems testing pharmaceutical products, additives and other chemicals for their mutagenic action. Naturwissen schaften 49: 457 462 ( original in German).

Kato, M. 1963. Distribution and excretion of radiomanganese administered to the mouse. Q. J. Exp. Physiol. 48: 355 369.

Kaur, G., S. K. Hasan and R. C. Srivastava. 1980. The distribution of manganese 54 in fetal, young and adult rats. Toxicol. Lett. 5: 423 426.

Kawamura, C. L., H. Ikuta, S. Fukuzimi, et al. 1941. Intoxication by manganese in well water. Kitasato Arch. Exp. Med. 18: 145 169.

Kawano, J., D. M. Ney, C. L. Keen, et al. 1987. Altered high density lipoprotein composition in manganese deficient Sprague Dawley and Wistar rats. J. Nutr. 117: 902 906 ( as cited in ATSDR, 2000).

Keen, C. L., J. G. Bell and B. Lönnerdal. 1986. The effect of age on manganese uptake and retention from milk and infant formulas in rats. J. Nutr. 116( 3): 395 402.

Keen, C. L., J. L. Ensunsa, M. H. Watson, D. L. Baly, S. M. Donovan, M. H. Monaco, and M. S. Clegg. 1999. Nutritional aspects of manganese from experimental studies. Neurotoxicology 20: 213 224.

Kennedy, S. D. and R. G. Bryant. 1986. Manganese deoxyribonucleic acid binding modes: Nuclear magnetic relaxation dispersion results. Biophys. J. 50: 669 676.

Khan, K. N., J. M. Andress and P. F. Smith. 1997. Toxicity of subacute intravenous manganese chloride administration in beagle dogs. Toxicol. Pathol. 25( 4): 344 350.

Khandelwal, S., M. Ashquin and S. K. Tandon. 1984. Influence of essential elements on manganese intoxication. Bull. Environ. Contam. Toxicol. 32( 1): 10 19.

Kies, C. 1987. Nutritional Bioavailability of Manganese. American Chemical Society, Washington, D. C.

Kilburn, C. J. 1987. Manganese, malformations and motor disorders: findings in a manganeseexposed population. Neurotoxicology 8( 3): 421 429.

Kimura, M., N. Yagi and Y. Itokawa. 1978. Effect of subacute manganese feeding on serotonin metabolism in the rat. J. Toxicol. Environ. Health 4( 5 6): 701 707. 10 13 Manganese   February 2003 Klaassen, C. D. 1974. Biliary excretion of manganese in rats, rabbits, and dogs. Toxicol. Appl. Pharmacol. 29( 3): 458 468.

Komura, J. and M. Sakamoto. 1991. Short term oral administration of several manganese compounds in mice: physiological and behavioral alterations caused by different forms of manganese. Bull. Environ. Contam. Toxicol. 46( 6): 921 928.

Komura, J. and M. Sakamoto. 1993. Subcellular and gel chromatographic distribution of manganese in the mouse brain: Relation to the chemical form of chronically ingested manganese. Toxicol. Lett. 66( 3): 287 294 ( as cited in ATSDR, 2000).

Kondakis, X. G., N. Makris, M. Leotsinidis, M. Prinou, and T. Papapetropopulos. 1989. Possible health effects of high manganese concentration in drinking water. Arch. Environ. Health 44( 3): 175 178.

Kondakis, X. G. 1990. Professor, University of Patras, Greece. Letter to S. Velazquez, U. S. EPA, Cincinnati, OH. August 23 ( as cited in U. S. EPA, 1993).

Kondakis, X. G. 1993. Professor, University of Patras, Greece. Letter to S. Velazquez, U. S. EPA, Cincinnati, OH. June 7 ( as cited in U. S. EPA, 1993).

Kontur, P. J. and L. D. Fechter. 1985. Brain manganese, catecholamine turnover, and the development of startle in rats prenatally exposed to manganese. Teratology 32( 1): 1 11.

Kontur, P. J. and L. D. Fechter. 1988. Brain regional manganese levels and monoamine metabolism in manganese treated neonatal rats. Neurotoxicol. Teratol. 10( 4): 295 303.

Kostial, K., D. Kello, S. Jugo, et al. 1978. Influence of age on metal metabolism and toxicity. Environ. Health Perspect. 25: 81 86.

Kristensson, K., H. Eriksson, B. Lundh, et al. 1986. Effects of manganese chloride on the rat developing nervous system. Acta Pharmacol. Toxicol. ( Copenh.) 59( 5): 345 348.

Lai, J. C., T. K. Leung and L. Lim. 1981. Brain regional distribution of glutamic acid decarboxylase, choline acetyltransferase, and acetylcholinesterase in the rat: effects of chronic manganese chloride administration after two years. J. Neurochem. 36( 4): 1443 1448.

Lai, J. C., T. K. Leung, J. F. Guest, et al. 1982a. The effects of chronic manganese chloride treatment expressed as age dependent, transient changes in rat brain synaptosomal uptake of amines. J. Neurochem. 38( 3): 844 847.

Lai, J. C., T. K. Leung and L. Lim. 1982b. The ontogeny of acetylcholinesterase activities in rat brain regions and the effect of chronic treatment with manganese chloride. J. Neurochem. 39( 6): 1767 1769 [ abstract]. 10 14 Manganese   February 2003 Lai, J. C., T. K. Leung, and L. Lim. 1984. Differences in the neurotoxic effects of manganese during development and aging: Some observations on brain regional neurotransmitter and nonneurotransmitter metabolism in a developmental rat model of chronic manganese encephalopathy. Neurotoxicology 5: 37 47.

Larsen, L. E. and D. Grant. 1997. General toxicology of MnDPDP. Acta Radiol. 38 ( 4 Pt 2): 770 779.

Larsen, N. A., H. Pakkenberg, E. Damsgaard, et al. 1979. Topographical distribution of arsenic, manganese, and selenium in the normal human brain. J. Neurol. Sci. 42 ( 3): 407 416.

Laskey, J. W., G. L. Rehnberg, J. F. Hein, et al. 1982. Effects of chronic manganese ( Mn 3 O 4) exposure on selected reproductive parameters in rats. J. Toxicol. Environ. Health 9( 4): 677 687.

Laskey, J. W., G. L. Rehnberg, J. F. Hein, et al. 1985. Assessment of the male reproductive system in the preweanling rat following Mn 3 O 4 exposure. J. Toxicol. Environ. Health 15( 2): 339 350.

Lawrence, D. A. 1981. Heavy metal modulation of lymphocyte activities. I. In vitro effects of heavy metals on primary humoral immune responses. Toxicol. Appl. Pharmacol. 57: 439 451 ( as cited in ATSDR, 2000).

Layrargues, G. P., C. Rose, L. Spahr, et al. 1998. Role of manganese in the pathogenesis of portal systemic encephalopathy. Metab. Brain Dis. 13( 4): 311 317.

Leahy, P. P., and T. H. Thompson. 1994. The National Water Quality Assessment Program. U. S. Geological Survey Open File Report 94 70. 4 pp. Available on the Internet at: http:// water. usgs. gov/ nawqa/ NAWQA. OFR94 70. html. Last updated August 23, 2000.

Leung, T. K., J. C. Lai and L. Lim. 1981. The regional distribution of monoamine oxidase activities towards different substrates: effects in rat brain of chronic administration of manganese chloride and of ageing. J. Neurochem. 36( 6): 2037 2043.

Leung, T. K., J. C. Lai and L. Lim. 1982. The effects of chronic manganese feeding on the activity of monoamine oxidase in various organs of the developing rat. Comp. Biochem. Physiol. 71C ( 2): 223 228.

Liccione, J. J. and M. D. Maines. 1989. Manganese medicated increase in the rat brain mitochondrial cytochrome P 450 and drug metabolism activity: Susceptibility of the striatum. J. Pharmacol. Exp. Ther. 248: 222 228.

Lönnerdal, B., C. L. Keen, J. G. Bell, et al. 1987. Manganese uptake and retention: Experimental animal and human studies. In: Kies, C., ed., Nutritional Bioavailability of Manganese. American Chemical Society, Washington, D. C. pp. 9 20. 10 15 Manganese   February 2003 Lönnerdal, B. 1994. Manganese nutrition of infants. In: Klimis Tavantzis, D. J., ed., Manganese in Health and Disease. CRC Press, Boca Raton, FL, pp. 175 191.

Loranger S. and J. Zayed. 1994. Manganese and lead concentrations in ambient air and emission rates from unleaded and leaded gasoline between 1981 and 1992 in Canada: A comparative study. Atmos. Environ. 28: 1645 1651.

Loranger, S. and J. Zayed. 1995. Environmental and occupational exposure to manganese: A multimedia assessment. Int. Arch. Occup. Environ. Health. 67( 2): 101 110.

Loranger, S. and J. Zayed. 1997a. Environmental contamination and human exposure to airborne total respirable manganese in Montreal. J. Air Waste Mngt. Assoc. 47( 9): 983 989 [ Abstract].

Loranger, S., and J. Zayed. 1997b. Environmental contamination and human exposure assessment to manganese in the St. Lawrence River ecozone ( Quebec, Canada) using an environmental fate/ exposure model: GEOTOX. Environ. Res. 6( 1 2): 105 119.

Loranger, S., J. Zayed and E. Forget. 1994a. Manganese contamination in Montreal in relation with traffic density. Water Air Soil Pollut. 74: 385 396.

Loranger, S., G. Demers, G. Kennedy, et al. 1994b. The pigeon ( Columba livia) as a monitor of atmospheric manganese contamination from mobile sources. Arch. Environ. Contam. Toxicol. 27: 311 317.

Loranger, S., J. Zayed and G. Kennedy. 1995. Contribution of methylcyclopentadienyl manganese tricarbonyl ( MMT) to atmospheric Mn concentration near expressway: dispersion modeling estimations. Atmos. Environ. 29: 591 599.

Lynam D., G. Pfeifer, B. Fort, et al. 1994. Atmospheric exposure to manganese from use of methylcyclopentadienyl manganese tricarbonyl ( MMT) performance additive. Sci. Total Environ. 146/ 147: 103 109.

Lynam, D. R., J. W. Roos, G. D. Pfeifer, et al. 1999. Environmental effects and exposures to manganese from use of methylcyclopentadienyl manganese tricarbonyl ( MMT) in gasoline. Neurotoxicology 20( 2 3): 145 150.

Mahomedy, M. C., Y. H. Mahomedy, P. A. S. Canhan, et al. 1975. Methaemoglobinaemia following treatment dispensed by witch doctors. Anaesthesia 30: 190 193.

Mahoney, J. P. and W. J. Small. 1968. Studies on manganese. 3. The biological half life of radiomanganese in man and factors which affect this half life. J. Clin. Invest. 47( 3): 643 653.

Malecki E. A. and J. L. Greger. 1996. Manganese protects against heart mitochondrial lipid peroxidation in rats fed high levels of polyunsaturated fatty acids. J. Nutr. 126: 27 33. 10 16 Manganese   February 2003 Malecki, E. A., G. M. Radazanowski, T. J. Radazanowski, D. D. Gallahler, and J. L. Greger. 1996. Biliary manganese excretion in conscious rats is affected by acute and chronic manganese intake but not by dietary fat. J. Nutr. 126: 489 498.

Mandzgaladze, R. N. and M. I. Vasakidze. 1966. The effect of small doses of manganese compounds, nitrogenous organomercury pesticides and some anticoagulants in white rat bone marrow cells. Vopr. Gig. Tr. Profpatol. 10: 209 212 ( original in Russian).

Mandzgaladze, R. N. 1966. On the mutagenic properties of manganese compounds. Vopr. Gig. Tr. Profpatol. 10: 225 226 ( original in Russian).

Matrone, G., R. H. Hartman and A. J. Clawson. 1959. Studies of a manganese iron antagonism in the nutrition of rabbits and baby pigs. J. Nutr. 67: 309 317.

Maynard, L. S. and G. C. Cotzias. 1955. The partition of manganese among organs and intracellular organelles of the rat. J. Biol. Chem. 214: 489 495.

McDermott, S. D. and C. Kies. 1987. Manganese usage in humans as affected by use of calcium supplements. In: Kies, C., ed., Nutritional Bioavailability of Manganese. American Chemical Society, Washington, D. C. pp. 146 151.

Mella, H. 1924. The experimental production of basal ganglion symptomatology in macacus rhesus. Arch. Neurol. Psych. 11: 405 417.

Mena, I., K. Horiuchi and K. Burke. 1969. Chronic manganese poisoning: Individual susceptibility and absorption of iron. Neurology 19: 1000 1006.

Mena, I., J. Court, S. Fuenzalida, et al. 1970. Modification of chronic manganese poisoning. Treatment with L dopa or 5 OH tryptophane. N. Engl. J. Med. 282( 1): 5 10.

Mena, I. 1974. The role of manganese in human disease. Ann. Clin. Lab. Sci. 4( 6): 487 491.

Merck. 1983. The Merck Index, 10th Ed. Merck & Co., Inc. Rahway, N. J.

Minoia, C., E. Sabbioni, P. Apostoli, et al. 1990. Trace element reference values in tissues from inhabitants of the European community. I. A study of 46 elements in urine, blood and serum of Italian subjects. Sci. Total Environ. 95: 89 105 ( as cited in ATSDR, 2000).

Mirowitz, S. A. and T. J. Westrich. 1992. Basal ganglial signal intensity alterations: Reversal after discontinuation of parenteral manganese administration. Radiol. 185: 535 536.

Moran, J. 1975. The environmental implications of manganese as an alternative antiknock. # 750926, SAE Publications Division, Michigan. 10 17 Manganese   February 2003 Morganti, J. B., B. A. Lown, C. H. Stineman, et al. 1985. Uptake, distribution and behavioral effects of inhalation exposure to manganese ( MnO 2) in the adult mouse. Neurotoxicology 6( 1): 1 15.

Mortelmans, K., S. Haworth, T. Lawlor, et al. 1986. Salmonella mutagenicity test. II. Results from the testing of 270 chemicals. Environ. Mutagen. 8 ( Suppl. 7): 1 119 ( as cited in NTP, 1993).

Mustafa, S. J. and S. V. Chandra. 1971. Levels of 5 hydroxytryptamine, dopamine and norepinephrine in whole brain of rabbits in chronic manganese toxicity. J. Neurochem. 18( 6): 931 933 ( as cited in ATSDR, 2000).

Nachtman, J. P., R. E. Tubben and R. L. Commissaris. 1986. Behavioral effects of chronic manganese administration in rats: locomotor activity studies. Neurobehav. Toxicol. Teratol. 8( 6): 711 715.

Neff, N. H., R. E. Barrett and E. Costa. 1969. Selective depletion of caudate nucleus dopamine and serotonin during chronic manganese dioxide administration to squirrel monkeys. Experimentia 25: 1140 1141.

Newberne, P. M. 1973. Input and disposition of manganese in man. In: Medical and Biologic Effects of Environmental Pollutants: Manganese. National Academy of Sciences, Washington, D. C. pp. 77 82.

Newland, M. C., T. L. Ceckler, J. H. Kordower, et al. 1989. Visualizing manganese in the primate basal ganglia with magnetic resonance imaging. Exp. Neurol. 106( 3): 251 258.

Newland, M. C. and B. Weiss. 1992. Persistent effects of manganese on effortful responding and their relationship to manganese accumulation in the primate globus pallidus. Toxicol. Appl. Pharmacol. 113( 1): 87 97.

NIOSH. 1984. National Institute for Occupational Safety and Health. Registry of Toxic Effects of Chemical Substances. Prepared by Tracor Jitco, Inc., under Contract Number 210 81 8101. Rockville, MD.

Nishioka, H. 1975. Mutagenic activities of metal compounds in bacteria. Mutat. Res. 31: 185 189 ( as cited in ATSDR, 2000).

NTP. 1992. Toxicology and Carcinogenesis Studies of Manganese ( II) Sulfate Monohydrate ( CAS no. 10034 96 5) in F344/ N Rats and B6C3F 1 Mice ( Feed Studies). Draft Technical Report. NTP Tech. Rep. Ser. 428. National Toxicology Program, Research Triangle Park, NC.

NTP. 1993. Toxicology and Carcinogenesis Studies of Manganese ( II) Sulfate Monohydrate ( CAS no. 10034 96 5) in F344/ N Rats and B6C3F 1 Mice ( Feed Studies). NTP Tech. Rep. Ser. 428. National Toxicology Program, Research Triangle Park, NC. 10 18 Manganese   February 2003 Oberley, T. J., C. E. Piper and D. S. McDonald. 1982. Mutagenicity of metal salts in the L5178Y mouse lymphoma assay. J. Toxicol. Environ. Health 9: 367 376 ( as cited in ATSDR, 2000).

Olanow, C. W., P. F. Good, H. Shinotoh, et al. 1996. Manganese intoxication in the rhesus monkey: A clinical, imaging, pathologic, and biochemical study. Neurology 46: 492 498.

Oner, G., and U. K. Senturk. 1995. Reversibility of manganese induced learning defect in rats. Food Chem. Toxicol. 33: 559 563.

Ono, J., K. Harada, and R. Kodaka. 1995. Manganese deposition in the brain during long term parenteral nutrition. J Parent Enter Nutr 19: 310 312 ( as cited in ATSDR, 2000).

Orgel, A. and L. E. Orgel. 1965. Induction of mutations in bacteriophage T4 with divalent manganese. J. Mol. Biol. 14: 453 457 ( as cited in ATSDR, 2000).

Pagano, D. A. and E. Zeiger. 1992. Conditions for detecting the mutagenicity of divalent metals in Salmonella typhimurium. Environ. Mol. Mutagen. 19( 2): 139 146 ( as cited in ATSDR, 2000).

Pal, P. K., A. Samii, and D. B. Calne. 1999. Manganese neurotoxicity: A review of clinical features, imaging and pathology. Neurotoxicology 20: 227 238.

Papavasiliou, P. S., S. T. Miller and G. C. Cotzias. 1966. Role of liver in regulating distribution and excretion of manganese. Am. J. Physiol. 211( 1): 211 216.

Pappas, B. A., D. Zhang, C. M. Davidson, et al. 1997. Perinatal manganese exposure: behavioral, neurochemical, and histopathological effects in the rat. Neurotoxicol. Teratol. 19( 1): 17 25.

Pellizzari, E., C. Clayton, C. Rodes, et al. 1999. Particulate matter and manganese exposures in Toronto, Canada. Atmos. Environ. 33: 721 734.

Pennington, J. A., B. E. Young, D. B. Wilson, et al. 1986. Mineral content of foods and total diets: The selected minerals in food survey. J. Am. Diet Assoc. 86: 876 891.

Pennington, J. A., B. E. Young, and D. B. Wilson. 1989. Nutritional elements in the U. S. diet: Results for the Total Diet Study, 1982 1986. J. Am. Diet Assoc. 89: 659 664.

Perry, H. M., Jr., E. F. Perry, J. E. Purifoy, et al. 1973. A comparison of intra and interhepatic variability of trace metal concentrations in normal men. In: Trace Substances in Environmental Health, Proc. Univ. Missouri 7th Annual Conf. University of Missouri, Columbia, MO. pp. 281 288.

Pfeifer G., R. Harrison and D. Lynam. 1999. Personal exposures to airborne metals in London taxi drivers and office workers in 1995 and 1996. Sci. Total Environ. 235: 253 260. 10 19 Manganese   February 2003 Pierson, W., D. McKee, W. Brachaczek, et al. 1978. Methylcyclopentadienyl manganese tricarbonyl: effect on manganese emissions from vehicles on the road. J. Air Pollut. Control Assoc. 28: 692 693.

Pihl, R. O. and M. Parkes. 1977. Hair element content in learning disabled children. Science 198: 204 206.

Piver, W. 1974. Potential dilemma: The methods of meeting automotive exhaust emission standards of the Clean Air Act of 1970. Environ. Health Perspect. 8: 165 190.

Pollack, S., J. N. George, R. C. Reba, et al. 1965. The absorption of nonferrous metals in iron deficiency. J. Clin. Invest. 44: 1470 1473.

Powell, J., T. Borden and R. Thompson. 1998. In vitro mineral availability from digested tea: A rich dietary source of manganese. Analyst 123: 1721 1724.

Price, N. O., G. E. Bunce and R. W. Engel. 1970. Copper, manganese and zinc balance in preadolescent girls. Am. J. Clin. Nutr. 23: 258 260.

Qato, M. K. and M. D. Maines. 1985. Regulation of heme and drug metabolism activities in the brain by manganese. Biochem. Biophys. Res. Commun. 128( 1): 18 24.

Rabar, I. 1976. Some factors influencing manganese metabolism in rats. M. Sc. Thesis, Univ. Zagreb., Zagreb, Yugoslavia.

Rasmuson, A. 1985. Mutagenic effects of some water soluble metal compounds in a somatic eye color test system in Drosophila melanogaster. Mutat. Res. 157: 157 162 ( as cited in ATSDR, 2000).

Rehnberg, G. L., J. F. Hein, S. D. Carter, et al. 1980. Chronic manganese oxide administration to preweanling rats: manganese accumulation and distribution. J. Toxicol. Environ. Health 6( 1): 217 226.

Rehnberg, G. L., J. F. Hein, S. D. Carter, et al. 1981. Chronic ingestion of Mn 3 O 4 by young rats: tissue accumulation, distribution, and depletion. J. Toxicol. Environ. Health 7( 2): 263 272.

Rehnberg, G. L., J. F. Hein, S. D. Carter, et al. 1982. Chronic ingestion of Mn 3 O 4 by rats: tissue accumulation and distribution of manganese in two generations. J. Toxicol. Environ. Health 9( 2): 175 188.

Rehnberg, G. L., J. F. Hein, S. D. Carter, et al. 1985. Age dependent changes in gastrointestinal transport and retention of particulate manganese oxide in the rat. J Toxicol Environ Health 16: 887 899. 10 20 Manganese   February 2003 Ressler, T., J. Wong, and J. Roos. 1999. Manganese speciation in exhaust particulates of automobiles using MMT containing gasoline. J. Synchroton Radiation ( as cited in Lynam et al., 1999).

Riveros Rosas H., G. Pfeifer, D. Lynam, et al. 1997. Personal exposure to elements in Mexico City air. Sci. Total Environ. 198: 79 96.

Roels, H., R. Lauwerys, P. Genet, et al. 1987. Relationships between external and internal parameters of exposure to manganese in workers from a manganese oxide and salt producing plant. Am. J. Ind. Med. 11: 297 305 ( as cited in U. S. EPA, 1999a).

Roels, H. A., P. Ghyselen, J. P. Buchet, et al. 1992. Assessment of the permissible exposure level to manganese in workers exposed to manganese dioxide dust. Br. J. Ind. Med. 49( 1): 25 34.

Roels, H. A., G. Meiers, M. Delos, et al. 1997. Influence of the route of administration and the chemical form ( MnCl 2, MnO 2) on the absorption and cerebral distribution of manganese in rats. Arch. Toxicol. 71: 223 230.

Roels, H. A., M. I. Ortega Eslava, E. Ceulemans, A. Robert and D. Lison. 1999. Prospective study on the reversibility of neurobehavioral effects in workers exposed to manganese dioxide. Neurotoxicology 20: 255 271.

Rogers, R. R., R. J. Garner, M. M. Riddle, et al. 1983. Augmentation of murine natural killer cell activity by manganese chloride. Toxicol. Appl. Pharmacol. 70: 7 17 ( as cited in ATSDR, 2000).

Roos J. W., D. L. Denane, B. F. Fort, D. G. Grande, and K. L. Dykes. The effect of manganese oxides on OBD II catalytic converter monitoring. SAE Technical Paper Series # 942056, Warrendale, PA ( as cited in Lynam et al., 1999).

Roth, G. S. and R. C. Adleman. 1975. Age related changes in hormone binding by target cells and tissues: Possible role of altered adaptive responsiveness. Exp. Gerontol. 10: 1 11.

Ruoff, W. L. 1995. Relative bioavailability of manganese ingested in food or water. In: Proceedings: Workshop on the Bioavailability and Oral Toxicity of Manganese. Sponsored by the U. S. Environmental Protection Agency, Cincinnati, OH. August 30 31, 1994 ( as cited in U. S. EPA, 1999a).

Ryker, S. J. and A. K. Williamson. 1999. Pesticides in Public Supply Wells of Washington State. U. S. Geological Survey Fact Sheet 122 96.

Sánchez, D. J., J. L. Domingo, J. M. Llobet, and C. L. Keen. 1993. Maternal and developmental toxicity of manganese in the mouse. Toxicol. Lett. 69( 1): 45 52.

Sandström, B., L. Davidsson, A. Cederblad, et al. 1986. Manganese absorption and metabolism in man. Acta Pharmacol. Toxicol. ( Copenh.) 59( Suppl 7): 60 62. 10 21 Manganese   February 2003 Scheuhammer, A. M. and M. G. Cherian. 1981. The influence of manganese on the distribution of essential trace elements. I. Regional distribution of Mn, Na, K, Mg, Zn, Fe, and Cu in rat brain after chronic Mn exposure. Toxicol. Appl. Pharmacol. 61( 2): 227.

Scheuhammer, A. M. 1983. Chronic manganese exposure in rats: histological changes in the pancreas. J. Toxicol. Environ. Health 12( 2 3): 353 360.

Scheuhammer, A. M. and M. G. Cherian. 1983. The influence of manganese on the distribution of essential trace elements. II. The tissue distribution of manganese, magnesium, zinc, iron, and copper in rats after chronic manganese exposure. J. Toxicol. Environ. Health 12( 2 3): 361 370.

Schroeder, H. A., J. J. Balassa and I. H. Tipton. 1966. Essential trace metals in man: Manganese. A study in homeostasis. J. Chronic Dis. 19( 5): 545 571.

Schwartz, R., B. J. Apgar and E. M. Wein. 1986. Apparent absorption and retention of Ca, Cu, Mg, Mn, and Zn from a diet containing bran. Am. J. Clin. Nutr. 43: 444 455.

Segura Aguilar, J. and C. Lind. 1989. On the mechanism of the Mn3+ induced neurotoxicity of dopamine: Prevention of quinone derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem. Biol. Interact. 72( 3): 309 324.

Shacklette, H. T., and J. G. Boerngen. 1984. Element oncentrations in soils and other surficial materials of the coterminous United States. USGS Paper 1270. Washington, DC: US Govern. Printing Office, p. 6.

Shigan, S. A. and B. R. Vitvickaja. 1971. Experimental substantiation of permissible residual concentrations of potassium permanganate in drinking water. Gig. Sanit. 36: 15 18.

Shimkin, M. B. and G. D. Stoner. 1975. Lung tumors in mice: Application to carcinogenesis bioassay. Adv. Cancer Res. 21: 1 58.

Shukla, G. S. and S. V. Chandra. 1976. Manganese induced morphological and biochemical changes in the brain of iron deficient rats. Ind. Health 14: 87 92.

Shukla, G. S. and S. V. Chandra. 1977. Levels of sulfhydryls and sulfhydryl containing enzymes in brain, liver and testis of manganese treated rats. Arch. Toxicol. 37( 4): 319 325.

Shukla, G. S., S. Singh and S. V. Chandra. 1978. The interaction between manganese and ethanol in rats. Acta Pharmacol. Toxicol. ( Copenh.) 43( 5): 354 362.

Shukla, G. S., M. P. Dubey and S. V. Chandra. 1980. Managanese induced biochemical changes in growing versus adult rats. Arch. Environ. Contam. Toxicol. 9( 4): 383 391.

Shukla, G. S. and S. V. Chandra. 1987. Concurrent exposure to lead, manganese, and cadmium and their distribution to various brain regions, liver, kidney, and testis of growing rats. Arch. Environ. Contam. Toxicol. 16( 3): 303 310. 10 22 Manganese   February 2003 Sierra, P., S. Loranger, G. Kennedy, et al. 1995. Occupational and environmental exposure of automobile mechanics and non automotive workers to airborne manganese arising from the combustion of methylcyclopentadienyl manganese tricarbonyl ( MMT). Am. Ind. Hyg. Assoc. J. 56( 7): 713 716.

Simmon, V. F. and S. Ligon. 1977. In vitro microbiological mutagenicity studies of Ethyl Corporation compounds. Interim report. Stanford Research Institute, California.

Singh, I. 1984. Induction of gene conversion and reverse mutation by manganese sulphate and nickel sulphate in Saccharomyces cerevisiae. Mutat. Res. 137: 47 49 ( as cited in ATSDR, 2000).

Singh, J., R. Husain, S. K. Tandon, et al. 1974. Biochemical and histopathological alterations in early manganese toxicity in rats. Environ. Physiol. Biochem. 4( 1): 16 23.

Singh, J., S. V. Chandra and S. K. Tandon. 1975. Chelation in metal intoxication II: In vitro and in vivo effect of some compounds on brain, liver, and testis of rats treated with manganese sulphate. Bull. Environ. Contam. Toxicol. 14( 4): 497 503.

Singh, S., G. S. Shukla, R. S. Srivastava, et al. 1979. The interaction between ethanol and manganese in rat brain. Arch. Toxicol. 41( 4): 307 316.

Sitaramayya, A., N. Nagar and S. V. Chandra. 1974. Effect of manganese on enzymes in rat brain. Acta Pharmacol. Toxicol. ( Copenh.) 35( 3): 185 190.

Smeyers Verbeke, J., P. Bell, A. Lowenthal, et al. 1976. Distribution of Mn in human brain tissue. Clin. Chim. Acta 68( 3): 343 347.

Smialowicz, R. J., R. W. Luebke, R. R. Rogers, et al. 1985. Manganese chloride enhances natural cell mediated immune effector cell function: Effects on macrophages. Immunopharmacology 9: 1 11 ( as cited in ATSDR, 2000).

Smialowicz, R. J., R. R. Rogers, M. M. Riddle, et al. 1987. Effects of manganese, calcium, magnesium, and zinc on nickel induced suppression of murine natural killer cell activity. J. Toxicol. Environ. Health 20: 67 80 ( as cited in ATSDR, 2000).

Smith, S. E., M. Medlicott and G. H. Ellis. 1944. Manganese deficiency in the rabbit. Arch. Biochem. Biophys. 4: 281 289 ( as cited in ATSDR, 2000).

Smyth, H. F., C. P. Carpenter, C. S. Weil, et al. 1969. Range finding toxicity data: List VII. J. Am. Ind. Hyg. Assoc. 30: 470 476.

Snyder, R. D. 1988. Role of active oxygen species in metal induced DNA strand breakage in human diploid fibroblasts. Mutat. Res. 193( 3): 237 246. 10 23 Manganese   February 2003 Spencer, H., C. R. Asmussen, R. B. Holtzman, et al. 1979. Metabolic balances of cadmium, copper, manganese, and zinc in man. Am. J. Clin. Nutr. 32( 9): 1867 1875.

Srisuchart, B., M. J. Taylor and R. P. Sharma. 1987. Alteration of humoral and cellular immunity in manganese chloride treated mice. J. Toxicol. Environ. Health 22: 91 99 ( as cited in ATSDR, 2000).

Stauber, J. L., T. M. Florence and W. S. Webster. 1987. The use of scalp hair to monitor manganese in aborigines from Groote Eylandt. Neurotoxicology 8( 3): 431 435.

Stoner, G. D., M. B. Shimkin, M. C. Troxell, et al. 1976. Test for carcinogenicity of metallic compounds by the pulmonary tumor response in strain A mice. Cancer Res. 36( 5): 1744 1747.

Strause, L. G., J. Hegenauer, P. Saltman, et al. 1986. Effects of long term dietary manganese and copper deficiency on rat skeleton. J. Nutr. 116: 135 141 ( as cited in ATSDR, 2000).

Sumino, K., K. Hayakawa, T. Shibata, et al. 1975. Heavy metals in normal Japanese tissues. Amounts of 15 heavy metals in 30 subjects. Arch. Environ. Health 30( 10): 487 494.

Suzuki, Y. 1974. Studies on excessive oral intake of manganese. II. Minimum dose for manganese accumulation in mouse organ. Shikoku Acta Med. 30: 32 45.

Suzuki, Y., T. Mouri, K. Nishiyama, et al. 1975. Study of subacute toxicity of manganese dioxide in monkeys. Tokushima J. Exp. Med . 22: 5 10.

Szakmáry, E., G. Ungvary, A. Hudak, et al. 1995. Developmental effect of manganese in rat and rabbit. Cent Eur J Occup Environ Med 1: 149 159.

Tanaka, Y. 1982. Manganese: Its possible significance in childhood nutrition in relation to convulsive disorders. J. Am. Coll. Nutr. 1: 113.

Ter Haar, G., M. Griffing, M. Brandt, D. G. Oderding, and M. Kapron. 1975. Methylcyclopentadienyl manganese tricarbonyl as an antiknock: Composition and fate of manganese exhaust products. J. Air Pollut. Control Assoc. 25: 858 860.

Thomson, A. B., D. Olatunbosun and L. S. Valverg. 1971. Interrelation of intestinal transport system for manganese and iron. J. Lab. Clin. Med. 78( 4): 642 655.

Tichy, M., M. Cikrt and J. Havrdova. 1973. Manganese binding in rat bile. Arch. Toxikol. 30( 3): 227 236.

Tipton, I. H. and M. J. Cook. 1963. Trace elements in human tissue. Part II. Adult subjects from the United States. Health Phys. 9: 103 145 ( as cited in ATSDR, 2000). 10 24 Manganese   February 2003 Tjälve, H., J. Henriksson, J. Tallkvist, B. S. Larsson, and N. G. Lindquist. 1996. Uptake of manganese and cadmium from the nasal mucosa into the central nervous system via olfactory pathway in rats. Pharmacol. Toxicol. 79: 347 356.

Treinen, K. A. and W. F. Blazak. 1995. Delvelopmental toxicity of WIN 59010 2 in Sprague Dawley rats. Toxicology 15: 160 161 [ Abstract].

Trumbo, P., A. A. Yates, S. Schlicker and M. Poos. 2001. Dietary reference intakes: Vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc 101: 294 301.

Ulitzur, C. E. and M. Barak. 1988. Detection of genotoxicity of metallic compounds by the bacterial bioluminescence test. J. Biol. Chem. 2: 95 99 ( as cited in ATSDR, 2000).

Umeda, M. and M. Nishimura. 1979. Inducibility of chromosomal aberrations by metal compounds in cultured mammalian cells. Mutat. Res. 67: 221 223.

U. S. EPA. 1975. Scientific and technical assessment report on manganese. North Carolina: U. S. Environmental Protection Agency, Office of Research and Development. EPA 600/ 6 75 002.

U. S. EPA. 1984. Health Assessment Document for Manganese. U. S. Environmental Protection Agency, Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office. EPA 600/ 8 83 013F. Cincinnati, OH.

U. S. EPA. 1986a. Guidelines for Carcinogenic Risk Assessment. U. S. Environmental Protection Agency. Fed. Reg. 51( 185): 33992 34003.

U. S. EPA. 1986b. Guidelines for the Health Risk Assessment of Chemical Mixtures. U. S. Environmental Protection Agency. Federal Register 51( 185): 34014 34025.

U. S. EPA. 1986c. Guidelines for Mutagenicity Risk Assessment. U. S. Environmental Protection Agency. Federal Register 51( 185): 34006 34012.

U. S. EPA. 1986d. Reference Values for Risk Assessment. U. S. Environmental Protection Agency. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office. Cincinnati, OH.

U. S. EPA. 1988. Recommendations for and Documentation of Biological Values for Use in Risk Assessment. U. S. Environmental Protection Agency, Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment, Cincinnati, OH. EPA/ 600/ 6 87 008. NTIS PB88 179874/ AS, February 1988.

U. S. EPA. 1990. Comments on the use of methylcyclopentadienyl manganese tricarbonyl in unleaded gasoline. North Carolina: U. S. Environmental Protection Agency, Office of Research and Development. 10 25 Manganese   February 2003 U. S. EPA. 1991a. Guidelines for Developmental Toxicity Risk Assessment. U. S. Environmental Protection Agency. Federal Register 56: 63798 63826.

U. S. EPA. 1991b. Summary of workshop discussions at the manganese and methylcyclopentadienyl manganese tricarbonyl ( MMT) conference, 12 15 March 1991. North Carolina: U. S. Environmental Protection Agency, Office of Research and Development.

U. S. EPA. 1993. Drinking Water Criteria Document for Manganese. Final Draft. U. S. Environmental Protection Agency, Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment. ECAO CIN D008. Cincinnati, OH.

U. S. EPA. 1994a. Drinking Water Criteria Document for Manganese. U. S. Environmental Protection Agency, Office of Water, Research and Development. September, 1993. Updated: March, 1994.

U. S. EPA. 1994b. Peer Review and Peer Involvement at the U. S. Environmental Protection Agency. Signed by the U. S. EPA Administrator, Carol A. Browner, June 7.

U. S. EPA 1995. Use of the Benchmark Dose Approach in Health Risk Assessment. U. S. Environmental Protection Agency. EPA/ 630/ R 94/ 007.

U. S. EPA. 1996a. Manganese. Integrated Risk Information System. ( IRIS). U. S. Environmental Protection Agency. Available at http:// www. epa. gov/ iris. Last revised December 1, 1996.

U. S. EPA 1996b. Proposed Guidelines for Carcinogen Risk Assessment. U. S. Environmental Protection Agency, Office of Research and Development, Washington, D. C. EPA/ 600/ P 92/ 003C.

U. S. EPA. 1996c. Guidelines for Reproductive Toxicity Risk Assessment. U. S. Environmental Protection Agency, Office of Research and Development, Washington, D. C. EPA/ 630/ R 96/ 009.

U. S. EPA. 1996d. Exposure Factors Handbook. Vol. I General Factors. EPA/ 600/ 8 89/ 043. Washington, DC.

U. S. EPA. 1996e. Emergency Planning and Community Right to Know Section 313, List of Toxic Chemicals. Available on the internet at: http:// www. epa. gov/ tri/ chemls2. pdf. Last modified March 23, 2000. Link to site at: http:// www. epa. gov/ tri/ chemical. htm U. S. EPA. 1997. U. S. Environmental Protection Agency. Announcement of the Draft Drinking Water Contaminant Candidate List; Notice. Fed. Reg. 62( 193): 52193. October 6.

U. S. EPA. 1998. U. S. Environmental Protection Agency. Announcement of the Drinking Water Contaminant Candidate List; Final Rule. Fed. Reg. 63( 274): 10273. March 2. 10 26 Manganese   February 2003 U. S. EPA. 1998a. Guidelines for Neurotoxicity Risk Assessment. U. S. Environmental Protection Agency. Federal Register 63( 93): 26926 26954.

U. S. EPA. 1998b. Science Policy Council Handbook: Peer Review. U. S. Environmental Protection Agency, Office of Science Policy, Office of Research and Development, Washington, D. C. EPA/ 100? B 98/ 001.

U. S. EPA. 1999a. A Review of Contaminant Occurrence in Public Water Systems. EPA Report/ 816 R 99/ 006. U. S. Environmental Protection Agency, Office of Water, 78 pp.

U. S. EPA. 1999b. U. S. Environmental Protection Agency. Guidelines for Carcinogen Risk Assessment. National Center for Environmental Assessment, Risk Assessment Forum, Washington, D. C. NCEA F 0644. July 1999. Available on line at: http:// www. epa. gov/ ncea/ raf/ car2sab. htm U. S. EPA. 2000a. What is the Toxic Release Inventory. Available on the Internet at: http:// www. epa. gov/ tri/ general. htm Last modified February 28, 2000.

U. S. EPA. 2000b. TRI Explorer: Trends. Available on the Internet at: http:// www. epa. gov/ triexplorer/ trends. htm Last modified May 5, 2000.

U. S. EPA. 2000c. TRI Explorer: Are Year to Year Changes Comparable? Available on the Internet at: www. epa. gov/ triexplorer/ yearsum. htm Last modified May 5, 2000.

U. S. EPA. 2000d. The Toxic Release Inventory ( TRI) and Factors to Consider when Using TRI Data. Available on the Internet at: http:// www. epa. gov/ tri/ tri98/ 98over. pdf. Last modified August 11, 2000. Link to site at: http:// www. epa. gov/ tri/ tri98 U. S. EPA. 2000e. Water Industry Baseline Handbook, Second Edition ( Draft). March 17.

USGS. 2000. Mineral Commodity Summaries, February, 2000  Manganese. Available on the Internet at: http:// minerals. usgs. gov/ minerals/ pubs/ commodity/ manganese/ 420300. pdf USGS. 2001. USGS National Water Quality Assessment Data Warehouse. Available on the Internet at: http:// infotrek. er. usgs. gov/ pls/ nawqa/ nawqa. home. Last updated April 19, 2001 Valencia, H., J. M. Mason, R. C. Woodruff, et al. 1985. Chemical mutagenesis testing in Drosophila. III. Results of 48 coded compounds tested for the National Toxicology Program. Environ. Mutagen. 7: 325 348 ( as cited in ATSDR, 2000).

Vieregge, P., B. Heinzow, G. Korf, H. M. Teichert, P. Schleifenbaum and H. U. Mösinger. 1995. Long term exposure to manganese in rural well water has no neurological effects. Can. J. Neurol. Sci. 22: 286 289.

Wassermann, D. and M. Wassermann. 1977. The ultrastructure of the liver cell in subacute manganese administration. Environ Res. 14( 3): 379 390. 10 27 Manganese   February 2003 Wedler, F. C. 1994. Biochemical and nutritional role of manganese: An overview. In: Klimis Tavantzis, D. J., ed., Manganese in Health and Disease. Boca Raton, FL: CRC Press, Inc., pp. 1 36 ( as cited in ATSDR, 2000).

Weigand E., M. Kirchgessner, and U. Helbig. 1986. True absorption and endogenous fecal excretion of manganese in relation to its dietary supply in growing rats. Biol. Trace Elem. Res. 10: 265 279.

WHO. 1973. Trace Elements in Human Nutrition: Manganese. Technical Report Service, 532. World Health Organization, Geneva, Switzerland.

WHO. 1981. Environmental Health Criteria 17. Manganese. World Health Organization, Geneva, Switzerland.

Widdowson, E. M., H. Chan, G. E. Harrison, et al. 1972. Accumulation of Cu, Zn, Mn, Cr and Co in the human liver before birth. Biol. Neonate 20( 5): 360 367.

Wong, P. K. 1988. Mutagenicity of heavy metals. Bull. Environ. Contam. Toxicol. 40: 597 603 ( as cited in ATSDR, 2000).

Yamada, M., S. Ohno, I. Okayasu, et al. 1986. Chronic manganese poisoning: A neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol. ( Berl.) 70: 273 278.

Yamaguchi, M., K. Inomoto and Y. Soketa. 1986. Effect of essential trace metals on bone metabolism in weanling rats: Comparison with zinc and other metals' actions. Res. Exp. Med. 186: 337 342.

Yamamoto, H. and T. Suzuki. 1969. Chemical structure of manganese compounds and their biological effects. Jap. Assoc. Ind. Health, Fukuoka City, Japan, March 28 31.

Zakour, R. A. and B. W. Glickman. 1984. Metal induced mutagenesis in the lacI gene of Escherichia coli. Mutat. Res. 126: 9 18 ( as cited in ATSDR, 2000).

Zayed, J., M. Gerin, S. Loranger, et al. 1994. Occupational and environmental exposure of garage workers and taxi drivers to airborne manganese arising from the use of methylcyclopentadienyl manganese tricarbonyl ( MMT) in unleaded gasoline. Am. Ind. Hyg. Assoc. J. 55( 1): 53 58.

Zayed, J., M. Mikhail, S. Loranger, et al. 1996. Exposure of taxi drivers and office workers to total and respirable manganese in an urban environment. Am. Ind. Hyg. Assoc. J. 57( 4): 376 380.

Zayed, J, C. Thibault, L. Gareau, et al. 1999a. Airborne manganese particulates and methylcyclopentadienyl manganese tricarbonyl ( MMT) at selected outdoor sites in Montreal. Neurotoxicology 20( 2 3): 151 158. 10 28 Manganese   February 2003 Zayed, J., A. Vyskocil and G. Kennedy. 1999b. Environmental contamination and human exposure to manganese contribution of methylcyclopentadienyl manganese tricarbonyl in unleaded gasoline. Int. Arch. Occup. Environ. Health. 72: 7 13.

Zhang, G., D. Liu, and P. He. 1995. [ Effects of manganese on learning abilities in school children]. Chung Hua Yu Fang I Hsueh Tsa Chih 29: 156 158.

Zhernakova, T. V. 1967. Correlation between iron, manganese and copper content in the blood serum of healthy individuals. Bull. Exp. Biol. Med. 63: 47 48.

Zlotkin, S. H. and B. E. Buchanan. 1986. Manganese intakes in intravenously fed infants: Dosages and toxicity studies. Biol. Trace Elem. Res. 9: 271 279. A 1 Manganese   February 2003 APPENDIX A: Abbreviations and Acronyms ACGIH  American Conference of Governmental Industrial Hygienists ATSDR  Agency for Toxic Substances and Disease Registry CAS  Chemical Abstract Service CCL  Contaminant Candidate List CERCLA  Comprehensive Environmental Response, Compensation & Liability Act CMR  Chemical Monitoring Reform CWS  Community Water System DWEL  Drinking Water Equivalent Level EPA  Environmental Protection Agency EPCRA  Emergency Planning and Community Right to Know Act GW  ground water HA  Health Advisory HAL  Health Advisory Level HRL  Health Reference Level IOC  inorganic compound IRIS  Integrated Risk Information System MRL  Minimum Reporting Level NAWQA  National Water Quality Assessment Program NCOD  National Drinking Water Contaminant Occurrence Database NIOSH  National Institute for Occupational Safety and Health NIRS  National Inorganic and Radionuclide Survey NPDES  National Pollution Discharge Elimination System NPDWR  National Primary Drinking Water Regulation NTIS  National Technical Information Service NTNCWS  Non Transient Non Community Water System ppm  part per million PWS  Public Water System RCRA  Resource Conservation and Recovery Act SARA Title III  Superfund Amendments and Reauthorization Act SDWA  Safe Drinking Water Act SDWIS  Safe Drinking Water Information System SDWIS FED  the Federal Safe Drinking Water Information System STORET  Storage and Retrieval System SW  surface water TRI  Toxic Release Inventory UCM  Unregulated Contaminant Monitoring UCMR  Unregulated Contaminant Monitoring Regulation/ Rule UMRA  Unfunded Mandates Reform Act of 1995 URCIS  Unregulated Contaminant Monitoring Information System U. S. EPA  United States Environmental Protection Agency A 2 Manganese   February 2003 USGS  United States Geological Survey µ g/ L  micrograms per liter mg/ L  milligrams per liter > MCL  percentage of systems with exceedances > MRL  percentage of systems with detections B 1 Manganese   February 2003 NIRS Data  Manganese Occurrence in Public Water Systems ( HRL = 0.3 mg/ L)

State # Samples # Samples > MRL % Samples > MRL # Detects > 1/ 2 HRL % Detects > 1/ 2 HRL # Detects > HRL % Detects > HRL Min Detects ( mg/ L) Median Detects ( mg/ L)

AK 8 7 87.50% 2 25.00% 1 12.50% < 0.00 0.50 0.50 0.02 0.05 AL 8 4 50.00% 0.00% 0.00% < 0.00 0.05 0.05 0.00 0.01 AR 9 6 66.67% 0.00% 0.00% < 0.00 0.06 0.06 0.00 0.01 AZ 14 5 35.71% 1 7.14% 1 7.14% < 0.00 0.58 0.58 0.00 0.00 CA 60 26 43.33% 2 3.33% 1 1.67% < 0.00 0.65 0.65 0.00 0.01 CO 10 7 70.00% 0.00% 0.00% < 0.00 0.13 0.13 0.00 0.00 CT 23 18 78.26% 0.00% 0.00% < 0.00 0.09 0.09 0.00 0.01 DE 10 10 100.00% 0.00% 0.00% 0.00 0.08 0.08 0.00 0.01 FL 56 29 51.79% 0.00% 0.00% < 0.00 0.03 0.03 0.00 0.00 GA 23 9 39.13% 0.00% 0.00% < 0.00 0.05 0.05 0.00 0.02 IA 28 22 78.57% 5 17.86% 4 14.29% < 0.00 1.34 1.34 0.00 0.01 ID 12 1 8.33% 0.00% 0.00% < 0.00 0.13 0.13 0.13 0.13 IL 46 34 73.91% 1 2.17% 1 2.17% < 0.00 0.36 0.36 0.00 0.01 IN 19 18 94.74% 2 10.53% 1 5.26% < 0.00 0.33 0.33 0.01 0.03 KS 6 3 50.00% 1 16.67% 1 16.67% < 0.00 0.83 0.83 0.01 0.07 KY 8 6 75.00% 2 25.00% 1 12.50% < 0.00 0.50 0.50 0.00 0.02 LA 26 24 92.31% 3 11.54% 0.00% < 0.00 0.25 0.25 0.00 0.01 MA 7 6 85.71% 1 14.29% 0.00% < 0.00 0.19 0.19 0.00 0.00 MD 6 5 83.33% 0.00% 0.00% < 0.00 0.05 0.05 0.00 0.02 ME 7 6 85.71% 0.00% 0.00% < 0.00 0.04 0.04 0.00 0.01 MI 25 22 88.00% 2 8.00% 0.00% < 0.00 0.20 0.20 0.00 0.02 MN 19 17 89.47% 6 31.58% 4 21.05% < 0.00 0.63 0.63 0.01 0.09 MO 21 16 76.19% 3 14.29% 1 4.76% < 0.00 1.22 1.22 0.00 0.00 MS 26 21 80.77% 0.00% 0.00% < 0.00 0.09 0.09 0.00 0.01 MT 11 5 45.45% 1 9.09% 1 9.09% < 0.00 0.33 0.33 0.00 0.07 NC 44 33 75.00% 0.00% 0.00% < 0.00 0.09 0.09 0.00 0.01 ND 19 19 100.00% 3 15.79% 2 10.53% 0.00 0.63 0.63 0.00 0.01 NE 19 10 52.63% 3 15.79% 2 10.53% < 0.00 1.24 1.24 0.00 0.05 NH 10 8 80.00% 0.00% 0.00% < 0.00 0.11 0.11 0.01 0.05 NJ 6 2 33.33% 0.00% 0.00% < 0.00 0.09 0.09 0.01 0.05 NM 7 5 71.43% 1 14.29% 1 14.29% < 0.00 0.38 0.38 0.00 0.02 NV 2 1 50.00% 0.00% 0.00% < 0.00 0.00 0.00 0.00 0.00 NY 57 32 56.14% 4 7.02% 2 3.51% < 0.00 0.40 0.40 0.00 0.03 OH 25 19 76.00% 0.00% 0.00% < 0.00 0.13 0.13 0.00 0.02 OK 12 6 50.00% 0.00% 0.00% < 0.00 0.08 0.08 0.00 0.00 OR 8 5 62.50% 1 12.50% 0.00% < 0.00 0.17 0.17 0.00 0.01 PA 36 28 77.78% 7 19.44% 4 11.11% < 0.00 0.86 0.86 0.00 0.02 PR 1 1 100.00% 0.00% 0.00% 0.01 0.01 0.01 0.01 0.01 RI 1 1 100.00% 0.00% 0.00% 0.03 0.03 0.03 0.03 0.03 SC 18 11 61.11% 0.00% 0.00% < 0.00 0.07 0.07 0.00 0.01 SD 8 7 87.50% 2 25.00% 1 12.50% < 0.00 0.72 0.72 0.00 0.06 TN 9 8 88.89% 0.00% 0.00% < 0.00 0.08 0.08 0.00 0.00 TX 74 51 68.92% 0.00% 0.00% < 0.00 0.13 0.13 0.00 0.02 UT 10 4 40.00% 0.00% 0.00% < 0.00 0.02 0.02 0.00 0.00 VA 30 25 83.33% 0.00% 0.00% < 0.00 0.13 0.13 0.00 0.01 VT 12 8 66.67% 2 16.67% 2 16.67% < 0.00 0.33 0.33 0.00 0.00 WA 52 31 59.62% 3 5.77% 0.00% < 0.00 0.18 0.18 0.00 0.01 WI 30 24 80.00% 1 3.33% 0.00% < 0.00 0.18 0.18 0.00 0.02 WV 8 3 37.50% 1 12.50% 1 12.50% < 0.00 0.76 0.76 0.00 0.10 WY 3 3 100.00% 0.00% 0.00% 0.02 0.09 0.09 0.02 0.02 Total 989 672 67.95% 60 6.07% 32 3.24% < 0.00 0.63 1.34 0.00 0.01 The Health Reference Level ( HRL) is the estimated health effect level as provided by EPA for preliminary assessment for this work assignment.

The Health Reference Level ( HRL) used for Manganese is 0.28 mg/ L. This is a draft value for working review only. Manganese data were analyzed using two different HRLs and are, therefore, listed separately. Min Value ( mg/ L) 99% Value ( mg/ L) Max Value ( mg/ L)

"% > HRL" indicates the proportion of systems with any analytical results exceeding the concentration value of the HRL. PWS= Public Water Systems; GW= Ground Water ( PWS Source Water Type); SW= Surface Water ( PWS Source Water Type); MRL= Minimum Reporting Limit ( for laboratory analyses) APPENDIX B: Complete NIRS Data for Manganese


[Federal Register Volume 87, Number 81 (Wednesday, April 27, 2022)]
[Notices]
[Pages 25008-25009]
[FR Doc No: 2022-08962]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings

    Take notice that the Commission has received the following Natural
Gas Pipeline Rate and Refund Report filings:

Filings Instituting Proceedings

    Docket Numbers: RP22-833-000.
    Applicants: Southwest Gas Transmission Company, A Limited
Partnership.
    Description: Compliance filing: Pre-File Settlement in Lieu of Rate
Filing to be effective April 1, 2022 to be effective N/A.
    Filed Date: 4/20/22.
    Accession Number: 20220420-5172.
    Comment Date: 5 p.m. ET 5/2/22.

    Docket Numbers: RP22-834-000.
    Applicants: Columbia Gas Transmission, LLC.
    Description: Sec.  4(d) Rate Filing: Negotiated Rate and Non-
Conforming Agreement Clean Up to be effective 5/21/2022.
    Filed Date: 4/21/22.
    Accession Number: 20220421-5086.
    Comment Date: 5 p.m. ET 5/3/22.

    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    The filings are accessible in the Commission's eLibrary system
(https://elibrary.ferc.gov/idmws/search/fercgensearch.asp) by querying
the docket number.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/

docs-filing/efiling/filing-req.pdf. For other information, call (866)
208-3676 (toll free). For TTY, call<PHONE_NUMBER>.

    Dated: April 21, 2022.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2022-08962 Filed 4-26-22; 8:45 am]
BILLING CODE 6717-01-P